

Curriculum Vitae

Dr. Ibrahim Yaseen Hachim, MD, PhD

Education

- Ph.D, Cancer Research Program , Division of Experimental Medicine, Department of Medicine, Faculty of Medicine, McGill University, Montreal, Canada (2014- 2018).
- Master of Science, Histopathology, College of Medicine, Al-Nahrain University, Baghdad, Iraq (2003- 2005).
- M.B.Ch.B, Medicine, College of Medicine, Al-Nahrain University, Baghdad, Iraq (1995 – 2001).

Other certificates

- Certificate in Medical Education-Association for Medical Education in Europe (AMEE).
- Specialist B – Pathologist, Ministry of Health, United Arab Emirates (2015).

Work Experience

- **Assistant Professor** , Clinical Sciences Department, College of Medicine, University of Sharjah (2019)
- **Doctoral Internship in Clinical Trials**, Clinical Research Program, Lady Davis Institute, Sir Mortimer B. Davis J. General Hospital, Montreal, Canada (May 2018 - August 2018).
- **Ph.D student**, Cancer Research Program, Division of Experimental Medicine, Department of Medicine , Faculty of Medicine, McGill University, Montreal, Canada (2014- 2018).
- **Senior Lecturer**, Pathology department, RAK Medical & Health Sciences University, Ras AL-Khaimah, United Arab Emirates (2007- 2014).
- **Assistant lecturer**, Pathology department, College of Medicine, Al-Nahrain University, Baghdad, Iraq (2005 – 2006).
- **Resident house officer** – Physician, AL-Kadhymia Teaching Hospital, Baghdad, Iraq (2001- 2003).

Techniques:

- Immunohistochemistry, in situ hybridization, bioinformatics, data analysis, tissue culture, western Blot, qPCR, flow cytometry, RNA-Seq, ChIP-se, CRISPER/CAS9, in vivo models

Awards & Recognitions

- 1- Doctoral Studentship Award, Research Institute of the McGill University Health Center (RI-MUHC), Montreal, Canada (2017).
- 2- Doctoral Scholarship Award, The Fonds de recherche du Québec – Santé (FRQS) –, Montreal, Canada (2017-2018).
- 3- George G. Harris Fellowship in Cancer – Faculty of Medicine – McGill University, Montreal, Canada (2017).

- 4- Pauline Blinder Krupp Studentship Award for most promising clinical researchers (Oncology), the Montreal General Hospital Foundation, Montreal, Canada (2017).
- 5- Productivity Award, Experimental Medicine, McGill University, Montreal, Canada (April, 2017).
- 6- The paper entitled "**Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast**" was highlighted in the Health section of the most prestigious, **Wall Street Journal**.

Selected publication list:

1. **Hachim IY**, Hachim MY, Lopez VM, Lebrun JJ, Ali S., Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer, *Applied Immunohistochemistry & Molecular Morphology*. 2016 Apr;24 (4):238-45.
2. **Hachim, IY.**, Shams, A., Lebrun, J. J. & Ali, S. A Favorable Role of Prolactin in Human Breast Cancer Reveals Novel Pathway Based Gene Signatures Indicative of Tumor Differentiation and Favorable Patient Outcome. *Human Pathology*, doi: 10.1016/j.humpath.2016.02.010 (2016)
3. López-Ozuna VM, **Hachim IY**, Hachim MY, Lebrun JJ, Ali S., Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy, *Scientific Reports-Nature*, 2016 Aug 2;6:30934.
4. **Hachim IY**, Hachim MY, López-Ozuna VM, Ali S, Lebrun JJ., A dual prognostic role for the TGFβ receptors in human breast cancer, *Human Pathology*. 2016 Nov;57:140-151.
5. **Hachim IY**, Villatoro M , Canaf L ,Hachim MY, Boudreault, Haiub H , Ali S, Lebrun JJ. Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration. *Scientific reports-Nature*, 2017;7: 14976.
6. Binothman N, **Hachim IY**, Lebrun JJ, Ali S., CPSF6 is a Clinically Relevant Breast Cancer Vulnerability Target, *Ebiomedicine*, 2017 ,July 2017 ;21:65–78.
7. Tian J, Hachim MY, **Hachim IY**, Dai M, Lo C, Raffa FA, Ali S, Lebrun JJ. Cyclooxygenase-2 regulates TGFbeta-induced cancer stemness in triple-negative breast cancer. *Scientific Reports-Nature Rep.* 2017;7:40258
8. Hachim MY **Hachim IY**, Dai M, Ali S, Lebrun JJ, Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression." *Tumor Biology*, 2018, 40(1): 1010428317748254.
9. Jun Tian, Fatmah Al Raffa, Meiou Dai, Alaa Moamer, Baharak Khadang, **Ibrahim Y Hachim**, Khldoun Bakdounes, Suhad Ali, Bertrand Jean-Claude, and Jean-Jacques Lebrun : Dasatinib Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells , *British Journal of Cancer-Nature*, 2018 Nov 28. doi: 10.1038/s41416-018-0287-3.
10. López-Ozuna VM, **Hachim IY**, Hachim MY, Lebrun JJ, Ali S., Prolactin pro-differentiation pathway activation depletes cancer stem cells and inhibits tumorigenesis through the induction of cellular senescence in triple negative breast cancer (*submitted , Cancer letters*).
11. Alaa I. Moamer, **Ibrahim Y. Hachim**, Najat Binothman, Jean-Jacques Lebrun and Suhad Ali A role for kinesin-1 subunits KIF5B/KLC1 in regulating epithelial mesenchymal plasticity in breast tumorigenesis. *EBioMedicine*. 2019 Jun 13. pii: S2352-3964(19)30384-6. doi: 10.1016
12. **Hachim IY**, López-Ozuna VM, Hachim MY, Ali S., Lebrun JJ., Concomitant expression of PRLR with both TGFβ receptors are associated with less aggressive phenotype and prolonged survival in breast cancer patients , *Int J Mol Sci.* 2019 Apr 2;20(7). pii: E1640. doi: 10.3390/ijms20071640.
13. Sami MM, Hachim MY, **Hachim IY**, Elbarkouky AH, López-Ozuna VM. Nucleostemin expression in breast cancer is a marker of more aggressive phenotype and unfavorable patients' outcome: A STROBE-compliant article, *Medicine (Baltimore)*. 2019 Mar;98(9):e14744. doi: 10.1097/MD.00000000000014744.
14. **Hachim IY**, López-Ozuna VM, Hachim MY, Ali S., Lebrun JJ., New therapeutic application of Prolactin hormone in HER-2 overexpressing tumors through the suppression of HER- 2 enriched ALDH positive stem cells subpopulation, *Scientific reports-Nature (under review-Scientific Reports-Nature)*.

15. Sami Manal M, **Hachim Ibrahim Y**, Elbarkouky Ahmed H, Hachim Mahmood Y, Al Saadi Azan , Breast cancer profile in Ras Al Khaimah, United Arab Emirates – a histopathological and immunohistochemical study, Hamdan Medical Journal ,2014 , Volume: 7, 1 ; Pages 70-92.
16. **Ibrahim Y Hachim**, Yasser Essa Al Nuaimi, Ashraf Abd El Baky, Fatima Al Hashmi, Abeer Rahman, Saida Mazroei, Huda Hamouda Quality of Life in Patients Suffering from Thalassaemia in Ras Al Khaimah, United Arab Emirates, Hamdan Medical Journal .2014, Vol. 7, No. 1, Pages 1-7.